Policy effective 12/3/2014
Item 1: Chemotherapy
First coverage: Cytoxan combined with Adriamycin – 4 treatments,
one every 2 weeks.
Incidentals:
- low white blood cell count
- increased risk of bleeding from low platelet count
- hair loss
- nausea
- vomiting
- loss of appetite
- sores in mouth or on lips
- nail changes
- heart problems
- diarrhea
- irregular periods/ early menopause
Second coverage: Taxol combined with Herceptin – 12 treatments, one every week.
Incidentals:
- low white blood cell count
- susceptibility to infection
- allergic reactions
- hair loss
- numbness in the fingers and toes (neuropathy)
- weakness
- vomiting
- diarrhea
- mouth sores
- irregular periods/early menopause
- weakening of the heart muscle
- anemia
- abdominal pain
Item 2: Radiation – every day starting 4 weeks after chemotherapy.
Duration – 6 weeks
Item 3: Herceptin (antibody IV drug) - 17 treatments, one every 3 weeks.
HER2 (human epidermal receptor 2) inhibitor targeted therapy.
HER2 inhibitors work against
HER2-positive breast cancers by blocking the ability of the cancer cells to
receive chemical signals that tell the cells to grow.
Incidentals:
- weakening of the heart muscle
- low white blood cell count
- diarrhea
- anemia
- abdominal pain
Duration – One year
No comments:
Post a Comment